{
    "nct_id": "NCT05798611",
    "official_title": "A Phase II, Open-label, Multi-center, Basket Study of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy to Patients With Biologically Selected Advanced or Metastatic Solid Tumors (ARTIST)",
    "inclusion_criteria": "* Patients who have discontinued all previous treatments for cancer for at least 21 days or 5 half-lives (not including palliative radiotherapy at focal sites), whichever is shorter. Palliative radiotherapy must have completed 1 week prior to start of study treatment.\n* Resolution of all toxicities of prior therapy or surgical procedures to baseline or Grade 1 (except for hypothyroidism requiring medication, neuropathy, and alopecia, which must have resolved to Grade ≤2).\n* Have adequate organ function.\n* Patients of childbearing potential and patients with partners of childbearing potential are required to use highly effective contraception.\n* Have an estimated life expectancy of ≥12 weeks, in the judgment of the investigator.\n* Performance status of 0-1 on the Eastern Cooperative Oncology Group scale.\n* Have a non-irradiated tumor tissue sample (archival or newly obtained core biopsy of a tumor lesion) available.\n\nInclusion Criteria specific to each Arm\n\nInclusion Criteria for Arm 1 [ART0380 monotherapy (endometrial cancer patients)]\n\n* Persistent or recurrent EC with biological selection.\n* Patients should have received taxane/platinum chemotherapy unless contraindicated.\n* Measurable disease.\n\nInclusion Criteria for Arm 2 [ART0380 monotherapy (solid tumors patients)]\n\n* Advanced or metastatic solid cancers of any histology with biological selection.\n* If a Programmed cell death protein-1 /Programmed death-ligand-1 inhibitor (e.g., pembrolizumab) is approved and available for the patient's cancer, the patient should have received such treatment before participating in this study.\n* Radiologically evaluable disease.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients who are pregnant.\n* Prior treatment with an inhibitor of ATR, WEE1, checkpoint kinase 1 or PKMYT1.\n* Have a serious concomitant systemic disorder that would compromise the patient's ability to adhere to the protocol.\n* Have ongoing interstitial lung disease or pneumonitis (whether symptomatic or asymptomatic).\n* Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS) directed therapy shows no evidence of progression.\n* Have any major gastrointestinal issues that could impact absorption of ART0380.\n* Have a history of allergy or hypersensitivity to study drug components.\n* Have a significant bleeding disorder or vasculitis or had a Grade ≥3 bleeding episode within 12 weeks prior to enrollment.\n* Patients who plan to father a child while in the study or within 16 weeks (5 months in France) after the last administration of study treatment.",
    "miscellaneous_criteria": ""
}